Interaction of nuclear receptors with the Wnt/β-catenin/Tcf signaling axis: Wnt you like to know?

Endocrine Reviews

Volumn 26, Issue 7, 2005, Pages 898-915

  Mulholland, David J ^a,b   Dedhar, Shoukat ^b   Coetzee, Gerhard A ^c   Nelson, Colleen C ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGN 194204; ANDROSTANOLONE; ANTIANDROGEN; BETA CATENIN; BICALUTAMIDE; CALCITRIOL; CCAAT ENHANCER BINDING PROTEIN BETA; CELL NUCLEUS RECEPTOR; COLECALCIFEROL; DEXAMETHASONE; ESTROGEN RECEPTOR; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; LEXACALCITOL; LIOTHYRONINE; METRIBOLONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROGESTERONE RECEPTOR; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOID; SEOCALCITOL; SMALL INTERFERING RNA; T CELL FACTOR PROTEIN; THIAZOLIDINE DERIVATIVE; THYROID HORMONE RECEPTOR; TROGLITAZONE; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; WNT PROTEIN;

ADIPOGENESIS; BREAST CANCER; CELL ADHESION; CELL FUNCTION; CELL PROLIFERATION; CLINICAL TRIAL; COLON CANCER; COLON CARCINOGENESIS; COLORECTAL CANCER; CYTOLOGY; DEVELOPMENT; DRUG EFFICACY; ENDOCRINE CELL; HORMONE DEPENDENCE; HUMAN; IMMUNOTHERAPY; LUNG CANCER; MORPHOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; THYROID CANCER; TRANSCRIPTION INITIATION;

ANIMALS; BETA CATENIN; HUMANS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; TCF TRANSCRIPTION FACTORS; WNT PROTEINS;

EID: 28844439793     PISSN: 0163769X     EISSN: 0163769X     Source Type: Journal    
DOI: 10.1210/er.2003-0034     Document Type: Review

References (203)

1. McKenna NJ, O'Malley BW 2001 Nuclear receptors, coregulators, ligands, and selective receptor modulators: making sense of the patchwork quilt. Ann NY Acad Sci 949:3-5
2. McKenna NJ, O'Malley BW 2002 Minireview: nuclear receptor coactivators - an update. Endocrinology 143:2461-2465
3. Escriva H, Langlois MC, Mendonca RL, Pierce R, Laudet V 1998 Evolution and diversification of the nuclear receptor superfamily. Ann NY Acad Sci 839:143-146
4. Escriva H, Bertrand S, Laudet V 2004 The evolution of the nuclear receptor superfamily. Essays Biochem 40:11-26
5. Tata JR 2002 Signalling through nuclear receptors. Nat Rev Mol Cell Biol 3:702-710
6. Rochette-Egly C 2003 Nuclear receptors: integration of multiple signalling pathways through phosphorylation. Cell Signal 15:355-366
7. Grun F, Blumberg B 2003 Identification of novel nuclear hormone receptor ligands by activity-guided purification. Methods Enzymol 364:3-24
8. Yoshihara HA, Nguyen NH, Scanlan TS 2003 Design and synthesis of receptor ligands. Methods Enzymol 364:71-91
9. Okuno M, Kojima S, Matsushima-Nishiwaki R, Tsurumi H, Muto Y, Friedman SL, Moriwaki H 2004 Retinoids in cancer chemoprevention. Curr Cancer Drug Targets 4:285-298
10. Brown K 2002 Breast cancer chemoprevention: risk-benefit effects of the antioestrogen tamoxifen. Expert Opin Drug Saf 1:253-267
11. Weatherman RV, Fletterick RJ, Scanlan TS 1999 Nuclear-receptor ligands and ligand-binding domains. Annu Rev Biochem 68:559-581
12. Giroldi LA, Schalken JA 1993 Decreased expression of the intercellular adhesion molecule E-cadherin in prostate cancer: biological significance and clinical implications. Cancer Metastasis Rev 12:29-37
13. Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, Debruyne FM, Schalken JA 1994 Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 54:3929-3933
14. Potter E, Bergwitz C, Brabant G 1999 The cadherin-catenin system: implications for growth and differentiation of endocrine tissues. Endocr Rev 20:207-239
15. Semba S, Yamakawa M, Sasano H 2001 The cadherin-catenin superfamily in endocrine tumors. Endocr Pathol 12:1-13
16. Hecht A, Kemler R 2000 Curbing the nuclear activities of β-catenin. Control over Wnt target gene expression. EMBO Rep 1:24-28
17. Blaschuk OW, Rowlands TM 2002 Plasma membrane components of adherens junctions (Review). Mol Membr Biol 19:75-80
18. Peifer M, McEwen DG 2002 The ballet of morphogenesis: unveiling the hidden choreographers. Cell 109:271-274
19. Polakis P 2000 Wnt signaling and cancer. Genes Dev 14:1837-1851
20. Oving IM, Clevers HC 2002 Molecular causes of colon cancer. Eur J Clin Invest 32:448-457
21. Voeller HJ, Truica CI, Gelmann EP 1998 β-Catenin mutations in human prostate cancer. Cancer Res 58:2520-2523
22. Truica CI, Byers S, Gelmann EP 2000 β-Catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 60:4709-4713
23. Han G, Buchanan G, Ittmann M, Harris JM, Yu X, Demayo FJ, Tilley W, Greenberg NM 2005 Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci USA 102:1151-1156
24. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL 2004 Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33-39
25. Bhanot P, Brink M, Samos CH, Hsieh JC, Wang Y, Macke JP, Andrew D, Nathans J, Nusse R 1996 A new member of the frizzled family from Drosophila functions as a Wingless receptor. Nature 382:225-230
26. Bejsovec A 2005 Wnt pathway activation: new relations and locations. Cell 120:11-14
27. Doble BW, Woodgett JR 2003 GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116:1175-1186
28. Uren A, Reichsman F, Anest V, Taylor WG, Muraiso K, Bottaro DP, Cumberledge S, Rubin JS 2000 Secreted frizzled-related protein-1 binds directly to Wingless and is a biphasic modulator of Wnt signaling. J Biol Chem 275:4374-4382
29. Hsieh JC, Kodjabachian L, Rebbert ML, Rattner A, Smallwood PM, Samos CH, Nusse R, Dawid IB, Nathans J 1999 A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature 398:431-436
30. Dale TC, Weber-Hall SJ, Smith K, Huguet EL, Jayatilake H, Gusterson BA, Shuttleworth G, O'Hare M, Harris AL 1996 Compartment switching of WNT-2 expression in human breast tumors. Cancer Res 56:4320-4323
31. Lejeune S, Huguet EL, Hamby A, Poulsom R, Harris AL 1995 Wnt5a cloning, expression, and up-regulation in human primary breast cancers. Clin Cancer Res 1:215-222
32. Pai LM, Kirkpatrick C, Blanton J, Oda H, Takeichi M, Peifer M 1996 Drosophila α-catenin and E-cadherin bind to distinct regions of Drosophila armadillo. J Biol Chem 271:32411-32420
33. Clevers H 2000 Armadillo takes the APC shuttle. Nat Cell Biol 2:E177-E178
34. Davies G, Jiang WG, Mason MD 2001 The interaction between β-catenin, GSK3β and APC after motogen induced cell-cell dissociation, and their involvement in signal transduction pathways in prostate cancer. Int J Oncol 18:843-847
35. Henderson BR 2000 Nuclear-cytoplasmic shuttling of APC regulates β-catenin subcellular localization and turnover. Nat Cell Biol 2:653-660
36. Henderson BR, Fagotto F 2002 The ins and outs of APC and β-catenin nuclear transport. EMBO Rep 3:834-839
37. Rosin-Arbesfeld R, Cliffe A, Brabletz T, Bienz M 2003 Nuclear export of the APC tumour suppressor controls β-catenin function in transcription. EMBO J 22:1101-1113
38. van de Wetering M, Oosterwegel M, Dooijes D, Clevers H 1991 Identification and cloning of TCF-1, a T lymphocyte-specific transcription factor containing a sequence-specific HMG box. EMBO J 10:123-132
39. Daniels DL, Weis WI 2005 β-Catenin directly displaces Groucho/TLE repressors from Tcf/Lef in Wnt-mediated transcription activation. Nat Struct Mol Biol 12:364-371
40. Takemaru KI, Moon RT 2000 The transcriptional coactivator CBP interacts with β-catenin to activate gene expression. J Cell Biol 149:249-254
41. Koh SS, Li H, Lee YH, Widelitz RB, Chuong CM, Stallcup MR 2002 Synergistic coactivator function by coactivator-associated arginine methyltransferase (CARM) 1 and β-catenin with two different classes of DNA-binding transcriptional activators. J Biol Chem 277:26031-26035
42. Roose J, Molenaar M, Peterson J, Hurenkamp J, Brantjes H, Moerer P, van de Wetering M, Destree O, Clevers H 1998 The Xenopus Wnt effector XTcf-3 interacts with Groucho-related transcriptional repressors. Nature 395:608-612
43. Cavallo RA, Cox RT, Moline MM, Roose J, Polevoy GA, Clevers H, Peifer M, Bejsovec A 1998 Drosophila Tcf and Groucho interact to repress Wingless signalling activity. Nature 395:604-608
44. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben-Ze'ev A 1999 The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 96:5522-5527
45. Brabletz T, Herrmann K, Jung A, Faller G, Kirchner T 2000 Expression of nuclear β-catenin and c-myc is correlated with tumor size but not with proliferative activity of colorectal adenomas. Am J Pathol 156:865-870
46. He TC, Chan TA, Vogelstein B, Kinzler KW 1999 PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99:335-345
47. Oosterwegel MA, van de Wetering ML, Holstege FC, Prosser HM, Owen MJ, Clevers HC 1991 TCF-1, a T cell-specific transcription factor of the HMG box family, interacts with sequence motifs in the TCR β and TCR δ enhancers. Int Immunol 3:1189-1192
48. Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld B, Polakis P, Matrisian LM 1999 The metalloproteinase matrilysin is a target of β-catenin transactivation in intestinal tumors. Oncogene 18:2883-2891
49. Mikami T, Saegusa M, Mitomi H, Yanagisawa N, Ichinoe M, Okayasu I 2001 Significant correlations of E-cadherin, catenin, and CD44 variant form expression with carcinoma cell differentiation and prognosis of extrahepatic bile duct carcinomas. Am J Clin Pathol 116:369-376
50. Behrens J 2000 Control of β-catenin signaling in tumor development. Ann NY Acad Sci 910:21-33; discussion, 33-35
51. Peifer M, Polakis P 2000 Wnt signaling in oncogenesis and embryogenesis - a look outside the nucleus. Science 287:1606-1609
52. van Es JH, Barker N, Clevers H 2003 You Wnt some, you lose some: oncogenes in the Wnt signaling pathway. Curr Opin Genet Dev 13:28-33
53. Barker N, Morin PJ, Clevers H 2000 The yin-yang of TCF/β-catenin signaling. Adv Cancer Res 77:1-24
54. Barker N, Clevers H 2000 Catenins, Wnt signaling and cancer. Bioessays 22:961-965
55. Hagen T, Di Daniel E, Culbert AA, Reith AD 2002 Expression and characterization of GSK-3 mutants and their effect on β-catenin phosphorylation in intact cells. J Biol Chem 277:23330-23335
56. Hart M, Concordet JP, Lassot I, Albert I, del los Santos R, Durand H, Perret C, Rubinfeld B, Margottin F, Benarous R, Polakis P 1999 The F-box protein β-TrCP associates with phosphorylated β-catenin and regulates its activity in the cell. Curr Biol 9:207-210
57. Liu J, Stevens J, Rote CA, Yost HJ, Hu Y, Neufeld KL, White RL, Matsunami N 2001 Siah-1 mediates a novel β-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. Mol Cell 7:927-936
58. Matsuzawa SI, Reed JC 2001 Siah-1, SIP, and Ebi collaborate in a novel pathway for β-catenin degradation linked to p53 responses. Mol Cell 7:915-926
59. Fodde R, Smits R, Clevers H 2001 APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer 1:55-67
60. Liu W, Dong X, Mai M, Seelan RS, Taniguchi K, Krishnadath KK, Halling KC, Cunningham JM, Boardman LA, Qian C, Christensen E, Schmidt SS, Roche PC, Smith DI, Thibodeau SN 2000 Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating β-catenin/TCF signalling. Nat Genet 26:146-147
61. Kikuchi A 2003 Tumor formation by genetic mutations in the components of the Wnt signaling pathway. Cancer Sci 94:225-229
62. Brisken C, Heineman A, Chavarria T, Elenbaas B, Tan J, Dey SK, McMahon JA, McMahon AP, Weinberg RA 2000 Essential function of Wnt-4 in mammary gland development downstream of progesterone signaling. Genes Dev 14:650-654
63. Bocchinfuso WP, Hively WP, Couse JF, Varmus HE, Korach KS 1999 A mouse mammary tumor virus-Wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-α. Cancer Res 59:1869-1876
64. Li Y, Hively WP, Varmus HE 2000 Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer. Oncogene 19:1002-1009
65. Verras M, Brown J, Li X, Nusse R, Sun Z 2004 Wnt3a growth factor induces androgen receptor-mediated transcription and enhances cell growth in human prostate cancer cells. Cancer Res 64:8860-8866
66. Cronauer MV, Schulz WA, Ackermann R, Burchardt M 2005 Effects of WNT/β-catenin pathway activation on signaling through T-cell factor and androgen receptor in prostate cancer cell lines. Int J Oncol 26:1033-1040
67. Zhu H, Mazor M, Kawano Y, Walker MM, Leung HY, Armstrong K, Waxman J, Kypta RM 2004 Analysis of Wnt gene expression in prostate cancer: mutual inhibition by WNT11 and the androgen receptor. Cancer Res 64:7918-7926
68. Szeto W, Jiang W, Tice DA, Rubinfeld B, Hollingshead PG, Fong SE, Dugger DL, Pham T, Yansura DG, Wong TA, Grimaldi JC, Corpuz RT, Singh JS, Frantz GD, Devaux B, Crowley CW, Schwall RH, Eberhard DA, Rastelli L, Polakis P, Pennica D 2001 Overexpression of the retinoic acid-responsive gene Stra6 in human cancers and its synergistic induction by Wnt-1 and retinoic acid. Cancer Res 61:4197-4205
69. Tice DA, Szeto W, Soloviev I, Rubinfeld B, Fong SE, Dugger DL, Winer J, Williams PM, Wieand D, Smith V, Schwall RH, Pennica D, Polakis P 2002 Synergistic induction of tumor antigens by Wnt-1 signaling and retinoic acid revealed by gene expression profiling. J Biol Chem 277:14329-14335
70. Michalik L, Desvergne B, Wahli W 2004 Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer 4:61-70
71. Debril MB, Renaud JP, Fajas L, Auwerx J 2001 The pleiotropic functions of peroxisome proliferator-activated receptor γ. J Mol Med 79:30-47
72. Gerhold DL, Liu F, Jiang G, Li Z, Xu J, Lu M, Sachs JR, Bagchi A, Fridman A, Holder DJ, Doebber TW, Berger J, Elbrecht A, Moller DE, Zhang BB 2002 Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor-γ agonists. Endocrinology 143:2106-2118
73. Bennett CN, Ross SE, Longo KA, Bajnok L, Hemati N, Johnson KW, Harrison SD, MacDougald OA 2002 Regulation of Wnt signaling during adipogenesis. J Biol Chem 277:30998-31004
74. Ross SE, Hemati N, Longo KA, Bennett CN, Lucas PC, Erickson RL, MacDougald OA 2000 Inhibition of adipogenesis by Wnt signaling. Science 289:950-953
75. Ross SE, Erickson RL, Gerin I, DeRose PM, Bajnok L, Longo KA, Misek DE, Kuick R, Hanash SM, Atkins KB, Andresen SM, Nebb HI, Madsen L, Kristiansen K, MacDougald OA 2002 Microarray analyses during adipogenesis: understanding the effects of Wnt signaling on adipogenesis and the roles of liver X receptor α in adipocyte metabolism. Mol Cell Biol 22:5989-5999
76. Tetsu O, McCormick F 1999 β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398:422-426
77. Wang C, Pattabiraman N, Zhou JN, Fu M, Sakamaki T, Albanese C, Li Z, Wu K, Hulit J, Neumeister P, Novikoff PM, Brownlee M, Scherer PE, Jones JG, Whitney KD, Donehower LA, Harris EL, Rohan T, Johns DC, Pestell RG 2003 Cyclin D1 repression of peroxisome proliferator-activated receptor γ expression and transactivation. Mol Cell Biol 23:6159-6173
78. Moldes M, Zuo Y, Morrison RF, Silva D, Park BH, Liu J, Farmer SR 2003 Peroxisome-proliferator-activated receptor γ suppresses Wnt/β-catenin signalling during adipogenesis. Biochem J 376:607-613
79. Sharma C, Pradeep A, Wong L, Rana A, Rana B 2004 Peroxisome proliferator-activated receptor γ activation can regulate β-catenin levels via a proteasome-mediated and adenomatous polyposis coli-independent pathway. J Biol Chem 279:35583-35594
80. Sharma C, Pradeep A, Pestell RG, Rana B 2004 Peroxisome proliferator-activated receptor γ activation modulates cyclin D1 transcription via β-catenin-independent and cAMP-response element-binding protein-dependent pathways in mouse hepatocytes. J Biol Chem 279:16927-16938
81. Farrow B, Evers BM 2003 Activation of PPARγ increases PTEN expression in pancreatic cancer cells. Biochem Biophys Res Commun 301:50-53
82. Patel L, Pass I, Coxon P, Downes CP, Smith SA, Macphee CH 2001 Tumor suppressor and anti-inflammatory actions of PPARγ agonists are mediated via upregulation of PTEN. Curr Biol 11:764-768
83. Persad S, Troussard AA, McPhee TR, Mulholland DJ, Dedhar S 2001 Tumor suppressor PTEN inhibits nuclear accumulation of β-catenin and T cell/lymphoid enhancer factor 1-mediated transcriptional activation. J Cell Biol 153:1161-1174
84. Sharma M, Chuang WW, Sun Z 2002 Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3β inhibition and nuclear β-catenin accumulation. J Biol Chem 277:30935-30941
85. Jansson EA, Are A, Greicius G, Kuo IC, Kelly D, Arulampalam V, Pettersson S 2005 The Wnt/β-catenin signaling pathway targets PPARγ activity in colon cancer cells. Proc Natl Acad Sci USA 102:1460-1465
86. DuBois RN, Gupta R, Brockman J, Reddy BS, Krakow SL, Lazar MA 1998 The nuclear eicosanoid receptor, PPARγ, is aberrantly expressed in colonic cancers. Carcinogenesis 19:49-53
87. Lefebvre AM, Chen I, Desreumaux P, Najib J, Fruchart JC, Geboes K, Briggs M, Heyman R, Auwerx J 1998 Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 4:1053-1057
88. Saez E, Tontonoz P, Nelson MC, Alvarez JG, Ming UT, Baird SM, Thomazy VA, Evans RM 1998 Activators of the nuclear receptor PPARγ enhance colon polyp formation. Nat Med 4:1058-1061
89. Seed B 1998 PPARγ and colorectal carcinoma: conflicts in a nuclear family. Nat Med 4:1004-1005
90. Jenster G, van der Korput JA, Trapman J, Brinkmann AO 1992 Functional domains of the human androgen receptor. J Steroid Biochem Mol Biol 41:671-675
91. Brinkmann AO, Jenster G, Kuiper GG, Ris C, van Laar JH, van der Korput JA, Degenhart HJ, Trifiro MA, Pinsky L, Romalo G, Schweikert HU 1992 The human androgen receptor: structure/function relationship in normal and pathological situations. J Steroid Biochem Mol Biol 41:361-368
92. Lin HK, Hu YC, Yang L, Altuwaijri S, Chen YT, Kang HY, Chang C 2003 Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers. J Biol Chem 278:50902-50907
93. Heinlein CA, Chang C 2004 Androgen receptor in prostate cancer. Endocr Rev 25:276-308
94. Rahman M, Miyamoto H, Chang C 2004 Androgen receptor co-regulators in prostate cancer: mechanisms and clinical implications. Clin Cancer Res 10:2208-2219
95. Yang F, Li X, Sharma M, Sasaki CY, Longo DL, Lim B, Sun Z 2002 Linking β-catenin to androgen-signaling pathway. J Biol Chem 277:11336-11344
96. Song LN, Herrell R, Byers S, Shah S, Wilson EM, Gelmann EP 2003 β-Catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription. Mol Cell Biol 23:1674-1687
97. Mulholland DJ, Cheng H, Reid K, Rennie PS, Nelson CC 2002 The androgen receptor can promote β-catenin nuclear translocation independently of adenomatous polyposis coli. J Biol Chem 277:17933-17943
98. Mulholland DJ, Read JT, Rennie PS, Cox ME, Nelson CC 2003 Functional localization and competition between the androgen receptor and T-cell factor for nuclear β-catenin: a means for inhibition of the Tcf signaling axis. Oncogene 22:5602-5613
99. Pawlowski JE, Ertel JR, Allen MP, Xu M, Butler C, Wilson EM, Wierman ME 2002 Liganded androgen receptor interaction with β-catenin: nuclear co-localization and modulation of transcriptional activity in neuronal cells. J Biol Chem 277:20702-20710
100. Easwaran V, Pishvaian M, Salimuddin, Byers S 1999 Cross-regulation of β-catenin-LEF/TCF and retinoid signaling pathways. Curr Biol 9:1415-1418
101. Shah S, Hecht A, Pestell RG, Byers SW 2003 Trans-repression of β-catenin activity by nuclear receptors. J Biol Chem 278:48137-48145
102. Byers S, Pishvaian M, Crockett C, Peer C, Tozeren A, Sporn M, Anzano M, Lechleider R 1996 Retinoids increase cell-cell adhesion strength, β-catenin protein stability, and localization to the cell membrane in a breast cancer cell line: a role for serine kinase activity. Endocrinology 137:3265-3273
103. Vermeulen SJ, Bruyneel EA, van Roy FM, Mareel MM, Bracke ME 1995 Activation of the E-cadherin/catenin complex in human MCF-7 breast cancer cells by all-trans-retinoic acid. Br J Cancer 72:1447-1453
104. Palmer HG, Gonzalez-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, Quintanilla M, Cano A, de Herreros AG, Lafarga M, Munoz A 2001 Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of β-catenin signaling. J Cell Biol 154:369-387
105. Xiao JH, Ghosn C, Hinchman C, Forbes C, Wang J, Snider N, Cordrey A, Zhao Y, Chandraratna RA 2003 Adenomatous polyposis coli (APC)-independent regulation of β-catenin degradation via a retinoid X receptor-mediated pathway. J Biol Chem 278:29954-29962
106. Spangler PR, Delidow BC 1998 Co-regulation of pituitary tumor cell adhesion and prolactin gene expression by glucocorticoid. J Cell Physiol 174:115-124
107. Kouzmenko AP, Takeyama K, Ito S, Furutani T, Sawatsubashi S, Maki A, Suzuki E, Kawasaki Y, Akiyama T, Tabata T, Kato S 2004 Wnt/β-catenin and estrogen signaling converge in vivo. J Biol Chem 279:40255-40258
108. Darimont BD, Wagner RL, Apriletti JW, Stallcup MR, Kushner PJ, Baxter JD, Fletterick RJ, Yamamoto KR 1998 Structure and specificity of nuclear receptor-coactivator interactions. Genes Dev 12:3343-3356
109. McInerney EM, Rose DW, Flynn SE, Westin S, Mullen TM, Krones A, Inostroza J, Torchia J, Nolte RT, Assa-Munt N, Milburn MV, Glass CK, Rosenfeld MG 1998 Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation. Genes Dev 12:3357-3368
110. Shen HC, Buchanan G, Butler LM, Prescott J, Henderson M, Tilley WD, Coetzee GA 2005 GRIP1 mediates the interaction between the amino- and carboxyl-termini of the androgen receptor. Biol Chem 386:69-74
111. He B, Wilson EM 2002 The NH(2)-terminal and carboxyl-terminal interaction in the human androgen receptor. Mol Genet Metab 75:293-298
112. Chang CY, McDonnell DP 2002 Evaluation of ligand-dependent changes in AR structure using peptide probes. Mol Endocrinol 16:647-660
113. Hulsken J, Birchmeier W, Behrens J 1994 E-cadherin and APC compete for the interaction with β-catenin and the cytoskeleton. J Cell Biol 127:2061-2069
114. Huber AH, Nelson WJ, Weis WI 1997 Three-dimensional structure of the armadillo repeat region of β-catenin. Cell 90:871-882
115. El-Tanani M, Fernig DG, Barraclough R, Green C, Rudland P 2001 Differential modulation of transcriptional activity of estrogen receptors by direct protein-protein interactions with the T cell factor family of transcription factors. J Biol Chem 276:41675-41682
116. Ohta T, Tajima H, Yachie A, Yokoyama K, Elnemr A, Fushida S, Kitagawa H, Kayahara M, Nishimura G, Miwa K, Yamamoto M, Terada T, Ohkuma S 1999 Activated lansoprazole inhibits cancer cell adhesion to extracellular matrix components. Int J Oncol 15:33-39
117. Shah S, Pishvaian MJ, Easwaran V, Brown PH, Byers SW 2002 The role of cadherin, β-catenin, and AP-1 in retinoid-regulated carcinoma cell differentiation and proliferation. J Biol Chem 277:25313-25322
118. Masiello D, Chen SY, Xu Y, Verhoeven MC, Choi E, Hollenberg AN, Balk SP 2004 Recruitment of β-catenin by wild type or mutant androgen receptors correlates with ligand stimulated growth of prostate cancer cells. Mol Endocrinol 18:2388-2401
119. Chesire DR, Ewing CM, Gage WR, Isaacs WB 2002 In vitro evidence for complex modes of nuclear β-catenin signaling during prostate growth and tumorigenesis. Oncogene 21:2679-2694
120. Chesire DR, Isaacs WB 2002 Ligand-dependent inhibition of β-catenin/TCF signaling by androgen receptor. T cell factor. Oncogene 21:8453-8469
121. Cho SH, Oh CD, Kim SJ, Kim IC, Chun JS 2003 Retinoic acid inhibits chondrogenesis of mesenchymal cells by sustaining expression of N-cadherin and its associated proteins. J Cell Biochem 89:837-847
122. Verras M, Sun Z 2005 β-Catenin is involved in insulin-like growth factor 1-mediated transactivation of the androgen receptor. Mol Endocrinol 19:391-398
123. Kojima S, Suzuki H, Akakura K, Shimbo M, Ichikawa T, Ito H 2004 Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol 171:679-683
124. Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ 2003 Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 21:2673-2678
125. Bierie B, Nozawa M, Renou JP, Shillingford JM, Morgan F, Oka T, Taketo MM, Cardiff RD, Miyoshi K, Wagner KU, Robinson GW, Hennighausen L 2003 Activation of β-catenin in prostate epithelium induces hyperplasias and squamous transdifferentiation. Oncogene 22:3875-3887
126. Gounari F, Signoretti S, Bronson R, Klein L, Sellers WR, Kum J, Siermann A, Taketo MM, von Boehmer H, Khazaie K 2002 Stabilization of β-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia. Oncogene 21:4099-4107
127. Rios-Doria J, Kuefer R, Ethier SP, Day ML 2004 Cleavage of β-catenin by calpain in prostate and mammary tumor cells. Cancer Res 64:7237-7240
128. He B, Kemppainen JA, Voegel JJ, Gronemeyer H, Wilson EM 1999 Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain. J Biol Chem 274:37219-37225
129. Hwang TS, Han HS, Hong YC, Lee HJ, Paik NS 2003 Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients. Pathol Int 53:74-80
130. van Diest PJ, Michalides RJ, Jannink L, van der Valk P, Peterse HL, de Jong JS, Meijer CJ, Baak JP 1997 Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. Am J Pathol 150:705-711
131. Shigemasa K, Tanimoto H, Parham GP, Parmley TH, Ohama K, O'Brien TJ 1999 Cyclin D1 overexpression and p53 mutation status in epithelial ovarian cancer. J Soc Gynecol Investig 6:102-108
132. Sui L, Tokuda M, Ohno M, Hatase O, Hando T 1999 The concurrent expression of p27(kip1) and cyclin D1 in epithelial ovarian tumors. Gynecol Oncol 73:202-209
133. Natsume H, Sasaki S, Kitagawa M, Kashiwabara Y, Matsushita A, Nakano K, Nishiyama K, Nagayama K, Misawa H, Masuda H, Nakamura H 2003 β-Catenin/Tcf-1-mediated transactivation of cyclin D1 promoter is negatively regulated by thyroid hormone. Biochem Biophys Res Commun 309:408-413
134. Shiraishi T, Watanabe M, Muneyuki T, Nakayama T, Morita J, Ito H, Kotake T, Yatani R 1998 A clinicopathological study of p53, p21 (WAF1/CIP1) and cyclin D1 expression in human prostate cancers. Urol Int 61:90-94
135. Aaltomaa S, Eskelinen M, Lipponen P 1999 Expression of cyclin A and D proteins in prostate cancer and their relation to clinicopathological variables and patient survival. Prostate 38:175-182
136. Gumbiner LM, Gumerlock PH, Mack PC, Chi SG, deVere White RW, Mohler JL, Pretlow TG, Tricoli JV 1999 Overexpression of cyclin D1 is rare in human prostate carcinoma. Prostate 38:40-45
137. Reutens AT, Fu M, Wang C, Albanese C, McPhaul MJ, Sun Z, Balk SP, Janne OA, Palvimo JJ, Pestell RG 2001 Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner. Mol Endocrinol 15:797-811
138. Petre CE, Wetherill YB, Danielsen M, Knudsen KE 2002 Cyclin D1: mechanism and consequence of androgen receptor co-repressor activity. J Biol Chem 277:2207-2215
139. Petre-Draviam CE, Cook SL, Burd CJ, Marshall TW, Wetherill YB, Knudsen KE 2003 Specificity of cyclin D1 for androgen receptor regulation. Cancer Res 63:4903-4913
140. Knudsen KE, Cavenee WK, Arden KC 1999 D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability. Cancer Res 59:2297-2301
141. Cullen DA, Killick R, Leigh PN, Gallo JM 2004 The effect of polyglutamine expansion in the human androgen receptor on its ability to suppress β-catenin-Tcf/Lef dependent transcription. Neurosci Lett 354:54-58
142. Castagnetta L, Traina A, Campisi I, Calabro M, Maratta A, Saetta A, Agostara B, Mezzatesta N 2002 Androgen receptor status in nontumoral and malignant human colorectal tissues. Ann NY Acad Sci 963:322-325
143. Neuman E, Ladha MH, Lin N, Upton TM, Miller SJ, DiRenzo J, Pestell RG, Hinds PW, Dowdy SF, Brown M, Ewen ME 1997 Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol 17:5338-5347
144. Zwijsen RM, Buckle RS, Hijmans EM, Loomans CJ, Bernards R 1998 Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes Dev 12:3488-3498
145. Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, Bernards R, Michalides RJ 1997 CDK-independent activation of estrogen receptor by cyclin D1. Cell 88:405-415
146. Barnes DM, Gillett CE 1998 Cyclin D1 in breast cancer. Breast Cancer Res Treat 52:1-15
147. Frame S, Cohen P 2001 GSK3 takes centre stage more than 20 years after its discovery. Biochem J 359:1-16
148. Kim L, Kimmel AR 2000 GSK3, a master switch regulating cell-fate specification and tumorigenesis. Curr Opin Genet Dev 10:508-514
149. Ding VW, Chen RH, McCormick F 2000 Differential regulation of glycogen synthase kinase 3β by insulin and Wnt signaling. J Biol Chem 275:32475-32481
150. Salas TR, Kim J, Vakar-Lopez F, Sabichi AL, Troncoso P, Jenster G, Kikuchi A, Chen SY, Shemshedini L, Suraokar M, Logothetis CJ, DiGiovanni J, Lippman SM, Menter DG 2004 Glycogen synthase kinase-3 β is involved in the phosphorylation and suppression of androgen receptor activity. J Biol Chem 279:19191-19200
151. Wang L, Lin HK, Hu YC, Xie S, Yang L, Chang C 2004 Suppression of androgen receptor-mediated transactivation and cell growth by the glycogen synthase kinase 3β in prostate cells. J Biol Chem 279:32444-32452
152. Rogatsky I, Waase CL, Garabedian MJ 1998 Phosphorylation and inhibition of rat glucocorticoid receptor transcriptional activation by glycogen synthase kinase-3 (GSK-3). Species-specific differences between human and rat glucocorticoid receptor signaling as revealed through GSK-3 phosphorylation. J Biol Chem 273:14315-14321
153. Liao X, Thrasher JB, Holzbeierlein J, Stanley S, Li B 2004 Glycogen synthase kinase-3β activity is required for androgen-stimulated gene expression in prostate cancer. Endocrinology 145:2941-2949
154. Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ, Trapman J 1998 Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 58:2720-2723
155. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R 1997 PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943-1947
156. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV 1997 Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15:356-362
157. Carson JP, Kulik G, Weber MJ 1999 Antiapoptotic signaling in LNCaP prostate cancer cells: a survival signaling pathway independent of phosphatidylinositol 3′-kinase and Akt/protein kinase B. Cancer Res 59:1449-1453
158. Manin M, Baron S, Goossens K, Beaudoin C, Jean C, Veyssiere G, Verhoeven G, Morel L 2002 Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells. Biochem J 366:729-736
159. Lin HK, Yeh S, Kang HY, Chang C 2001 Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci USA 98:7200-7205
160. Ohigashi T, Mizuno R, Nakashima J, Marumo K, Murai M 2005 Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN-mutated prostate cancer cells. Prostate 62:61-68
161. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H 1994 Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54:5474-5478
162. Ohta T, Elnemr A, Yamamoto M, Ninomiya I, Fushida S, Nishimura G, Fujimura T, Kitagawa H, Kayahara M, Shimizu K, Yi S, Miwa K 2002 Thiazolidinedione, a peroxisome proliferator-activated receptor-γ ligand, modulates the E-cadherin/β-catenin system in a human pancreatic cancer cell line, BxPC-3. Int J Oncol 21:37-42
163. Amir AL, Barua M, McKnight NC, Cheng S, Yuan X, Balk SP 2003 A direct β-catenin independent interaction between androgen receptor and T cell factor 4. J Biol Chem 278:30828-30834
164. Meggouh F, Lointier P, Saez S 1991 Sex steroid and 1,25-dihydroxyvitamin D3 receptors in human colorectal adenocarcinoma and normal mucosa. Cancer Res 51:1227-1233
165. Mehta K 2003 Retinoids as regulators of gene transcription. J Biol Regul Homeost Agents 17:1-12
166. Edward M, Gold JA, Mackie RM 1992 Retinoic acid-induced inhibition of metastatic melanoma cell lung colonization and adhesion to endothelium and subendothelial extracellular matrix. Clin Exp Metastasis 10:61-67
167. Hoosein NM, Brattain DE, McKnight MK, Childress KE, Chakrabarty S, Brattain MG 1988 Comparison of the antiproliferative effects of transforming growth factor-β, N,N-dimethylformamide and retinoic acid on a human colon carcinoma cell line. Cancer Lett 40:219-232
168. O'Dwyer PJ, Ravikumar TS, McCabe DP, Steele Jr G 1987 Effect of 13-cis-retinoic acid on tumor prevention, tumor growth, and metastasis in experimental colon cancer. J Surg Res 43:550-557
169. 1. Endocrinology 138:1491-1497
170. Li Y, Wu L, Wang X, Chen WS 2004 [Effects of retinoic acid on the signal transduction of β-catenin /Tcf of cultured bronchial epithelial cells]. Zhonghua Yi Xue Za Zhi 84:1130-1131
171. Li Y, Wu R, Wang X, Chen W 2004 Effects of retinoic acid on the β-catenin/TCF pathway in cultured porcine tracheobronchial epithelial cells. J Huazhong Univ Sci Technolog Med Sci 24:421-423,432
172. Kallakury BV, Sheehan CE, Winn-Deen E, Oliver J, Fisher HA, Kaufman Jr RP, Ross JS 2001 Decreased expression of catenins (α and β), p120 CTN, and E-cadherin cell adhesion proteins and E-cadherin gene promoter methylation in prostatic adenocarcinomas. Cancer 92:2786-2795
173. Diaz GD, Paraskeva C, Thomas MG, Binderup L, Hague A 2000 Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res 60:2304-2312
174. Garland CF, Comstock GW, Garland FC, Helsing KJ, Shaw EK, Gorham ED 1989 Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet 2:1176-1178
175. Newmark HL, Lipkin M 1992 Calcium, vitamin D, and colon cancer. Cancer Res 52:2067s-2070s
176. Smith CL, Onate SA, Tsai MJ, O'Malley BW 1996 CREB binding protein acts synergistically with steroid receptor coactivator-1 to enhance steroid receptor-dependent transcription. Proc Natl Acad Sci USA 93:8884-8888
177. Fronsdal K, Engedal N, Slagsvold T, Saatcioglu F 1998 CREB binding protein is a coactivator for the androgen receptor and mediates cross-talk with AP-1. J Biol Chem 273:31853-31859
178. Tao YS, Edwards RA, Tubb B, Wang S, Bryan J, McCrea PD 1996 β-Catenin associates with the actin-bundling protein fascin in a noncadherin complex. J Cell Biol 134:1271-1281
179. Wong V, Ching D, McCrea PD, Firestone GL 1999 Glucocorticoid down-regulation of fascin protein expression is required for the steroid-induced formation of tight junctions and cell-cell interactions in rat mammary epithelial tumor cells. J Biol Chem 274:5443-5453
180. Guan Y, Rubenstein NM, Failor KL, Woo PL, Firestone GL 2004 Glucocorticoids control β-catenin protein expression and localization through distinct pathways that can be uncoupled by disruption of signaling events required for tight junction formation in rat mammary epithelial tumor cells. Mol Endocrinol 18:214-227
181. Zettl KS, Sjaastad MD, Riskin PM, Parry G, Machen TE, Firestone GL 1992 Glucocorticoid-induced formation of tight junctions in mouse mammary epithelial cells in vitro. Proc Natl Acad Sci USA 89:9069-9073
182. Buse P, Woo PL, Alexander DB, Reza A, Firestone GL 1995 Glucocorticoid-induced functional polarity of growth factor responsiveness regulates tight junction dynamics in transformed mammary epithelial tumor cells. J Biol Chem 270:28223-28227
183. Buse P, Woo PL, Alexander DB, Cha HH, Reza A, Sirota ND, Firestone GL 1995 Transforming growth factor-α abrogates glucocorticoid-stimulated tight junction formation and growth suppression in rat mammary epithelial tumor cells. J Biol Chem 270:6505-6514
184. Woo PL, Ching D, Guan Y, Firestone GL 1999 Requirement for Ras and phosphatidylinositol 3-kinase signaling uncouples the glucocorticoid-induced junctional organization and transepithelial electrical resistance in mammary tumor cells. J Biol Chem 274:32818-32828
185. Smith E, Coetzee GA, Frenkel B 2002 Glucocorticoids inhibit cell cycle progression in differentiating osteoblasts via glycogen synthase kinase-3β. J Biol Chem 277:18191-18197
186. Smith E, Frenkel B 2005 Glucocorticoids inhibit the transcriptional activity of LEF/TCF in differentiating osteoblasts in a glycogen synthase kinase-3β-dependent and -independent manner. J Biol Chem 280:2388-2394
187. Rubenstein NM, Guan Y, Woo PL, Firestone GL 2003 Glucocorticoid down-regulation of RhoA is required for the steroid-induced organization of the junctional complex and tight junction formation in rat mammary epithelial tumor cells. J Biol Chem 278:10353-10360
188. Miller LD, Park KS, Guo QM, Alkharouf NW, Malek RL, Lee NH, Liu ET, Cheng SY 2001 Silencing of Wnt signaling and activation of multiple metabolic pathways in response to thyroid hormone-stimulated cell proliferation. Mol Cell Biol 21:6626-6639
189. Richard-Parpaillon L, Heligon C, Chesnel F, Boujard D, Philpott A 2002 The IGF pathway regulates head formation by inhibiting Wnt signaling in Xenopus. Dev Biol 244:407-417
190. Franceschi RT 1992 Retinoic acid: morphogen or more mysteries? Nutr Rev 50:19-20
191. Noji S, Nohno T, Koyama E, Muto K, Ohyama K, Aoki Y, Tamura K, Ohsugi K, Ide H, Taniguchi S, Saito T 1991 Retinoic acid induces polarizing activity but is unlikely to be a morphogen in the chick limb bud. Nature 350:83-86
192. Liu T, Lee YN, Malbon CC, Wang HY 2002 Activation of the β-catenin/Lef-Tcf pathway is obligate for formation of primitive endoderm by mouse F9 totipotent teratocarcinoma cells in response to retinoic acid. J Biol Chem 277:30887-30891
193. Katoh M 2002 Regulation of WNT signaling molecules by retinoic acid during neuronal differentiation in NT2 cells: threshold model of WNT action (review). Int J Mol Med 10:683-687
194. Ralhan R, Kaur J 2003 Retinoids as chemopreventive agents. J Biol Regul Homeost Agents 17:66-91
195. Verma AK 2003 Retinoids in chemoprevention of cancer. J Biol Regul Homeost Agents 17:92-97
196. Chen RH, McCormick F 2001 Selective targeting to the hyperactive β-catenin/T-cell factor pathway in colon cancer cells. Cancer Res 61:4445-4449
197. Kim JS, Crooks H, Foxworth A, Waldman T 2002 Proof-of-principle: oncogenic β-catenin is a valid molecular target for the development of pharmacological inhibitors. Mol Cancer Ther 1:1355-1359
198. Chen G, Shukeir N, Potti A, Sircar K, Aprikian A, Goltzman D, Rabbani SA 2004 Up-regulation of Wnt-1 and β-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer 101:1345-1356
199. Wisniewski D, Strife A, Swendeman S, Erdjument-Bromage H, Geromanos S, Kavanaugh WM, Tempst P, Clarkson B 1999 A novel SH2-containing phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase (SHIP2) is constitutively tyrosine phosphorylated and associated with src homologous and collagen gene (SHC) in chronic myelogenous leukemia progenitor cells. Blood 93:2707-2720
200. Maira SM, Galetic I, Brazil DP, Kaech S, Ingley E, Thelen M, Hemmings BA 2001 Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane. Science 294:374-380
201. Cardona-Gomez P, Perez M, Avila J, Garcia-Segura LM, Wandosell F 2004 Estradiol inhibits GSK3 and regulates interaction of estrogen receptors, GSK3, and β-catenin in the hippocampus. Mol Cell Neurosci 25:363-373
202. Inadera H, Dong HY, Matsushima K 2002 WISP-2 is a secreted protein and can be a marker of estrogen exposure in MCF-7 cells. Biochem Biophys Res Commun 294:602-608
203. Liu J, Farmer SR 2004 Regulating the balance between peroxisome proliferator-activated receptor γ and β-catenin signaling during adipogenesis. A glycogen synthase kinase 3β phosphorylation-defective mutant of β-catenin inhibits expression of a subset of adipogenic genes. J Biol Chem 279:45020-45027